Skip to main content
OpenTrials
Completed

NCT Number: NCT02004314

Chloroquine as a Modulator of T Cell Immune Activation

This study will evaluate the effect of chloroquine in individuals infected with HIV. Researchers will aim to determine if chloroquine treatment in participants whose viral loads are suppressed on combination antiretroviral therapy (ART), results in improved immune activation and CD4 cell recovery.

The study will recruit 20 individuals and will last approximately 44 weeks. Eligible participants will receive an oral dose of chloroquine (250 mg) once daily from week 8 through week 32. All participants will be asked to have rectal biopsy samples (week 0 and week 32) to study T cell immune activation in the mucosa rectal site.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Montreal Chest Institute, McGill University Health Centre

Montreal, Quebec, H3A1A1, Canada

About this study

Clinical data has identified chloroquine as a potential modulator of immune activation. The study's dose of chloroquine is the same as the dose recommended for patients having autoimmune diseases. In these autoimmune cases, a daily dose of chloroquine at 250 mg for 12 weeks has shown improvement in symptoms and decreases in inflammatory cytokines synthesis and a reduction in TLR -mediated immune activation. Study findings could help provide information about where and under what circumstances chloroquine treatment may reduce T cell activation and help restore circulating CD4 T cells.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented HIV infection by Western Blot, EIA assays or viral load assay.
  • Aged between 18 and 65 years.
  • Viral load less than 50 copies per ml for at least the previous 36 weeks.
  • CD4 cell count less than or equal to 350 cells per litre.
  • On stable ART
  • Vital signs, physical examination and laboratory results do not exhibit evidence diseases such as advanced cirrhosis or advanced liver
  • Karnofsky performance status greater than or equal to 80 per cent.
  • Participant does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with chloroquine.
  • Able to give informed consent.

Exclusion criteria

  • Active AIDS events in the last 3 months
  • Co-infection with active hepatitis B or C virus.
  • Current use or use within four weeks prior to the baseline visit, of cytotoxic agents, systemic corticosteroids or any immuno-modulatory agents.
  • Current use within four weeks prior to the chloroquine therapy the following medications: methadone, chlorpromazine, cimetidine, cyclosporin, methotrexate and penicillanime.
  • Psychiatric or cognitive disturbance or illness that could preclude compliance with the study.
  • Patient with clinically significant hemophilia and Von-Willebrand disease and any severe bleeding disorder.
  • Experimental HIV immune based therapy within 6 months of screening visit.
  • Allergic reaction to chloroquine.
  • A history of retinitis or any retinal problem.
  • Subjects with G6PD deficiency, porphyria, psoriasis, cirrhosis, hearing deficiency (including tinnitus), myopathy and cardiomyopathy.
  • Pregnant and breast-feeding women.

Treatment and study plan

Chloroquine

Drug

Primary outcomes

  1. The expression of CD38 on CD8 circulating T cells

    Time frame: 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone

    To assess whether the expression of CD38 on CD8 circulating T cells will be reduced and whether circulating CD4 T cell recovery will be enhanced after 24 weeks of chloroquine treatment in adults whose HIV replication is suppressed by ART.

Secondary outcomes

  1. Safety of chloroquine treatment measured by adverse events, hematology and serum chemistries and Amsler grid test.

    Time frame: 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone

    Safety of chloroquine treatment measured by adverse events, hematology and serum chemistries and Amsler grid test

Sponsors and collaborators

Lead sponsor

CIHR Canadian HIV Trials Network

Network

Registry information

Official study title

Chloroquine as a Modulator of T Cell Immune Activation to Improve CD4 Recovery in HIV-infected Participants Receiving Antiretroviral Therapy: A Proof-of-concept Study

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Dec 9, 2013
Registry last updated
Dec 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.